CD274 and neoplasm: Looking forward, the biomarker landscape is rapidly expanding to include novel circulating factors (e.g., glypican 3, PD-L1 expression, tumor-infiltrating lymphocytes, circulating tumor cells, circulating tumor DNA), genomic and transcriptomic signatures from liquid biopsies, and radiologic features from medical imaging.